Galmed Pharmaceuticals, a clinical-stage biotech with a candidate for liver diseases (NASH), raised $38 million by offering 2.8 million shares at $13.50, within the range of $12.00 to $14.00. The company originally planned to offer 2.4 million shares. Galmed Pharmaceuticals plans to list on the NASDAQ under the symbol GLMD. Galmed Pharmaceuticals initially filed confidentially on 12/31/2013. Maxim Group LLC acted as sole bookrunner on the deal.
